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Dear Sir,
Despite the introduction of continuous
renal replacement therapies into the man-
agement of acute renal failure (ARF), inter-
mittent hemodialysis (IHD) remains the
most commonly used modality. The pattern
of prescription of dialyzer membranes for
ARF has changed dramatically with the ad-
vent of newer dialyzer membranes, which
differ from cellulosic membranes in their
potential to induce bioincompatibility reac-
tions. Two recent surveys indicate that only
8% of the patients with ARF requiring dialy-
sis were treated with cuprophane mem-
branes [1, 2]. It remains to be shown, wheth-
er the choice of a biocompatible membrane
for the treatment of ARF is merely an ex-
trapolation of the strategies used for chronic
renal failure, or whether it reflects evidence-
based therapy for ARF. The comprehensive
editorial review by Vanholder et al. [3] pro-
vides a useful addition to the literature, but
fails to comment conclusively on the poten-
tial impact of biocompatiblity for dialytic
therapy for ARF.
Five crucial clinical questions were not
adequately addressed:
(1) Does the same membrane type induce
different degrees of biocompatiblity when
used in ARF or end-stage renal disease? Up
until now, the reported experience is re-
stricted to a few studies demonstrating that
both the underlying disease precipitating
ARF as well as uremia may cause leukocyte
activation and diminish differences in clini-
cal outcome between membranes with inter-
medium or low biocompability [4].
(2) Is the natural course of ARF affected
by bioincompatible membranes? The aim of
the early studies was to test this hypothesis.
Mortality was only a secondary endpoint.
Our first abstract, for instance, dealt with
recovery from renal failure rather than mor-
tality [5]. A recent meta-analysis of con-
trolled trials by Karsou et al. [6] indicates
that the use of unsubstituted cellulosic mem-
branes has a negative impact on the survival
rate of patients with ARF. The overview of
published studies by Vanholder et al. [3],
including full papers or abstracts, clearly
shows that recovery of renal function was
delayed in patients receiving cuprophane
membranes by comparison to patients
treated with biocompatible membranes
(121/250(48%) vs. 101/161 (65%), despite
possible sources of variability including defi-
nition of biocompatibility of the membrane
tested, age, comorbid conditions, etiology of
ARF, presence of oliguria, the dialyzer char-
acteristics (e.g. surface area and flux), follow-
up duration and sample size.
(3) Are extreme differences in biocompa-
tibility of dialyzer membranes associated
with differences in outcome? The overwiew
of studies by Vanholder et al. [3], comparing
cuprophane and biocompatible membranes
clearly demonstrate that there is a significant
difference in mortality (199/4634 vs. 284/
536). The notion that there was not a single
study showing superiority of cuprophane
membranes by comparison with more bio-
compatible membranes is of great clinical
importance. The higher mortality associated
with the use of cuprophane membranes for
the treatment of ARF may by explained by
the delay in recovery of renal function. Re-
cent studies highlighted that renal failure per
se may increase morbidity and mortality in
patients with ARF [7, 8]. In the study by
Jörres et al. [9] 117 reasons for 66 fatalities
were given. By contrast, our study was based
on international definitions of septicemia/
systemic inflammatory response syndrome
and their lethal sequelae [10]. None of our
patients had septicemia or SIRS as cause of
renal failure nor were these syndromes
present at the initiation of dialysis treat-
ment. Fatalities were categorized either as
sepsis-related or nonrelated deaths. The
causes of death reported in our study were
checked by an independent ethical commit-
tee. These differences between both studies
highlight the notion that providing a pletho-
ra of data does not necessarily mean provid-
ing more information.
(4) Is the use of biocompatible mem-
branes harmful to patients with ARF? A
number of well-controlled prospective stud-
ies investigating this issue demonstrated no
detrimental effect of these membranes when
compared with cuprophane.
(5) Is it justified to recommend biocom-
patible membranes for ARF therapy? I
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would say yes to both intermediate and
highly biocompatible membranes. However,
choosing a more biocompatible membrane
means paying more for uncertain but poten-
tially improved outcomes in selected patient
groups. Given the astronomic costs of pro-
longed ICU management of critically ill pa-
tients with ARF, the costs of the chosen
membranes add little if any to the overall
costs [11].
The ‘scientific’ counter-arguments
against the use of biocompatible dialyzer
membranes in ARF reminds me of the argu-
ments used by the tobacco industry, who
claimed for decades that smoking wasn’t re-
ally dangerous for your health. The majority
of nephrologists or intensivists caring for pa-
tients with ARF have made a clear decision.
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